MYC and hepatocellular carcinoma: Zhu et al. (191) used a transgenic HCC mouse model driven by MYC overexpression and beta-catenin (encoded by CTNNB1) activation (termed MYC-lucOS; CTNNB1) (192), which shows resistance to anti-PD-1 immunotherapy, to evaluate the effect of the combination of anti-PD-L1 immunotherapy and anti-VEGF.